Blood Donation Eligibility: Platelet Dysfunction & Deferral Criteria

Individuals with platelet dysfunction (thrombocytopathy) are generally deferred from blood donation. This protects both the donor (bleeding risk from phlebotomy) and the recipient (ineffective platelet component).

Why Platelet Dysfunction Precludes Donation

  • Donor safety: Venipuncture (16–17 gauge needle) creates a vascular injury requiring platelet plug formation. Impaired platelet function → prolonged bleeding, hematoma, nerve injury risk.
  • Product quality: Whole blood donations are separated into components. Platelets from a dysfunctional donor would fail quality control (aggregation, pH, swirl) and be discarded—wasting red cells and plasma too.
  • Recipient safety: Transfused dysfunctional platelets would not provide hemostatic support to thrombocytopenic patients.

Conditions Causing Platelet Dysfunction

CategoryExamplesDonation Status
InheritedGlanzmann thrombasthenia, Bernard-Soulier, storage pool deficiency, von Willebrand disease (vWF affects platelet adhesion)Permanent deferral
Acquired – MedicationAspirin, NSAIDs, P2Y12 inhibitors (clopidogrel), GP IIb/IIIa inhibitors, SSRIs, antibiotics (some)Temporary deferral: 48 hrs–14 days post-dose (per drug)
Acquired – MedicalUremia, liver disease, myeloproliferative neoplasms, DIC, sepsis, cardiopulmonary bypassDeferred while active; reassess if resolved
AutoimmuneITP (immune thrombocytopenia) – low count + dysfunctionDeferred (count + function)

Screening at Donation

  • Health history questionnaire: bleeding disorders, medications, easy bruising
  • Hemoglobin/hematocrit check (fingerstick) – does not assess platelet function
  • Platelet count not routinely measured at whole blood donation
  • Plateletpheresis donors: count measured each donation; function inferred from quality control

When Donation May Be Possible

  • Medication-induced: After appropriate washout (e.g., aspirin 48 hrs, clopidogrel 7–10 days) and physician clearance.
  • Resolved acquired cause: e.g., post-sepsis recovery, normalized renal/liver function – with hematology clearance.
  • Carrier states: Heterozygous for inherited disorder with normal platelet function studies – case-by-case, medical director discretion.

Alternative Ways to Contribute

  • Volunteer at blood drives
  • Advocate for donation
  • Financial support to blood centers
  • Clinical trial participation (if eligible)

Bottom line: Active platelet dysfunction = deferral. Safety first for donor and recipient. Consult the blood center medical director for individual assessment.

Guidelines: AABB Standards, FDA Guidance, local blood center SOPs. This is not a substitute for donor screening interview.

Blood Disorders - Related Articles